P
The startup develops prophylactic vaccines and anticancer drugs using Virus-like Particle (VLP) technology, which is based on protein structure analysis and immunological research. This approach aims to enhance public health by providing effective preventive measures against infectious diseases and cancer.
Seoul, South Korea
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops prophylactic vaccines and anticancer drugs using Virus-like Particle (VLP) technology, which is based on protein structure analysis and immunological research. This approach aims to enhance public health by providing effective preventive measures against infectious diseases and cancer.